Drug intelligence / Profile preview

ebselen

Development stage
Phase 3
Lead developer
Sound
Modality
Small Molecules
01

Overview

Ebselen is a synthetic organoselenium compound with anti-inflammatory, antioxidant, and cytoprotective properties. It acts primarily as a glutathione peroxidase mimetic, reducing cellular damage from reactive oxygen species (ROS) and peroxynitrite. Ebselen also exhibits inhibitory activity against inositol monophosphatase (IMPase), cyclooxygenase 2 (COX2), leukotriene B4 receptor, prostaglandin receptors, and certain viral proteases. Its mechanisms make it of interest for neuroprotection and the treatment of conditions involving oxidative stress or inflammation. Ebselen has been investigated for Meniere’s disease (with positive Phase III results), bipolar disorder/mania, hearing loss (including noise-induced and sensorineural types), tinnitus, COVID infections, stroke recovery, depression, diabetes mellitus type 1 and type 2, among others. The most advanced clinical development is for Meniere’s disease as an oral capsule formulation called SPI‑1005[1][3][4][5][8].

Brand names
SPI-1005SPI1005SPI 1005
Other names
ebseleneebselenoebselenum2-pheny1-benzo[d]isoselenazol3(2H)-one2-pheny1-benzoisoselenazol3-oneHarmokisane
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)GPX4 (Glutathione peroxidase 4)PLpro (Papain-like protease)IMPA1 (Inositol Monophosphatase)LTB4R (Leukotriene B4 Receptor 1)TBXA2R (Thromboxane A2 receptor)

Beyond the preview

Go deeper on ebselen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ebselen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call